135 related articles for article (PubMed ID: 1663287)
1. Level of virulent virus excreted by infected pigs previously vaccinated with different glycoprotein deleted Aujeszky's disease vaccines.
Vannier P; Hutet E; Bourgueil E; Cariolet R
Vet Microbiol; 1991 Nov; 29(3-4):213-23. PubMed ID: 1663287
[TBL] [Abstract][Full Text] [Related]
2. Extent and duration of virulent virus excretion upon challenge of pigs vaccinated with different glycoprotein-deleted Aujeszky's disease vaccines.
Pensaert MB; De Smet K; De Waele K
Vet Microbiol; 1990 Apr; 22(2-3):107-17. PubMed ID: 2162094
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63.
van der Leek ML; Feller JA; Sorensen G; Isaacson W; Adams CL; Borde DJ; Pfeiffer N; Tran T; Moyer RW; Gibbs EP
Vet Rec; 1994 Jan; 134(1):13-8. PubMed ID: 8128561
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity in Aujeszky's disease virus structural glycoprotein gVI (gp50) in swine.
Mukamoto M; Watanabe I; Kobayashi Y; Icatlo FC; Ishii H; Kodama Y
Vet Microbiol; 1991 Oct; 29(2):109-21. PubMed ID: 1660638
[TBL] [Abstract][Full Text] [Related]
5. Air sampling procedure for evaluation of viral excretion level by vaccinated pigs infected with Aujeszky's disease (pseudorabies) virus.
Bourgueil E; Hutet E; Cariolet R; Vannier P
Res Vet Sci; 1992 Mar; 52(2):182-6. PubMed ID: 1316629
[TBL] [Abstract][Full Text] [Related]
6. Correlation between gI, gII, gIII, and gp 50 antibodies and virus excretion in vaccinated pigs infected with pseudorabies virus.
Eloit M; Vannier P; Hutet E; Fournier A
Arch Virol; 1992; 123(1-2):135-43. PubMed ID: 1312820
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of maternally immune pigs with a live Aujeszky's disease vaccine by coarse spray and other routes.
Chong YC; Ng FK
Vet Microbiol; 1994 Mar; 39(1-2):117-24. PubMed ID: 8203117
[TBL] [Abstract][Full Text] [Related]
8. Vaccination against pseudorabies with glycoprotein gI+ or glycoprotein gI- vaccine.
Vandeputte J; Chappuis G; Fargeaud D; Précausta P; Guillemin F; Brun A; Desmettre P; Stellmann C
Am J Vet Res; 1990 Jul; 51(7):1100-6. PubMed ID: 2167620
[TBL] [Abstract][Full Text] [Related]
9. Intranasal vaccination of pigs against Aujeszky's disease: protective immunity at 2 weeks, 2 months and 4 months after vaccination in pigs with maternal antibodies.
van Oirschot JT
Vet Microbiol; 1991 Apr; 27(2):103-13. PubMed ID: 1648282
[TBL] [Abstract][Full Text] [Related]
10. Influence of vaccine medium and vaccination schedules on the induction of active immunity against Aujeszky's disease in maternally immune pigs.
De Smet K; De Waele K; Pensaert M
Res Vet Sci; 1994 Jan; 56(1):89-94. PubMed ID: 8146460
[TBL] [Abstract][Full Text] [Related]
11. Intranasal vaccination of pigs against Aujeszky's disease: comparison with one or two doses of attenuated vaccines in pigs with high maternal antibody titres.
Van Oirschot JT
Res Vet Sci; 1987 Jan; 42(1):12-6. PubMed ID: 3029845
[TBL] [Abstract][Full Text] [Related]
12. Safety of an Aujeszky's disease vaccine based on deletion mutant strain 783 which does not express thymidine kinase and glycoprotein I.
van Oirschot JT; Terpstra C; Moormann RJ; Berns AJ; Gielkens AL
Vet Rec; 1990 Nov; 127(18):443-6. PubMed ID: 2177288
[TBL] [Abstract][Full Text] [Related]
13. Influence of passive immunity on pig immunization with deleted Aujeszky's disease vaccines measured by the amount of wild virus excretion after challenge.
Vannier P; Hutet E; Cariolet R
Vet Microbiol; 1995 Jan; 43(1):53-63. PubMed ID: 7716884
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of pigs against Aujeszky's disease by the intradermal route using live attenuated and inactivated virus vaccines.
Vannier P; Cariolet R
Vet Microbiol; 1991 Jan; 26(1-2):11-23. PubMed ID: 1850888
[TBL] [Abstract][Full Text] [Related]
15. Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease.
van Oirschot JT; Gielkens AL; Moormann RJ; Berns AJ
Vet Microbiol; 1990 Jun; 23(1-4):85-101. PubMed ID: 2169682
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of three doses of the genetically engineered Aujeszky's disease virus vaccine strain 783 in pigs with maternal antibodies.
Kimman TG
Vaccine; 1992; 10(6):363-5. PubMed ID: 1317982
[TBL] [Abstract][Full Text] [Related]
17. Intranasal vaccination of pigs against Aujeszky's disease: comparison with inactivated vaccines in pigs with low maternal antibody titres.
De Leeuw PW; Van Oirschot JT
Res Vet Sci; 1985 Jul; 39(1):34-8. PubMed ID: 2994188
[TBL] [Abstract][Full Text] [Related]
18. Oronasal challenge of fattening pigs after vaccination with an inactivated Aujeszky's disease vaccine.
Pensaert MB; Vandeputte J; Andries K
Res Vet Sci; 1982 Jan; 32(1):12-6. PubMed ID: 6283610
[TBL] [Abstract][Full Text] [Related]
19. Influence of vaccination on Aujeszky's disease virus and disease transmission.
Donaldson AI; Wardley RC; Martin S; Harkness JW
Vet Rec; 1984 Aug; 115(6):121-4. PubMed ID: 6089404
[TBL] [Abstract][Full Text] [Related]
20. Intranasal vaccination of pigs against Aujeszky's disease. 4. Comparison with one or two doses of an inactivated vaccine in pigs with moderate maternal antibody titres.
Van Oirschot JT; De Leeuw PW
Vet Microbiol; 1985 Aug; 10(5):401-8. PubMed ID: 2996212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
